Prothionamide and dapsone therapy in leprosy--a clinical study.
Combined therapy with prothionamide and dapsone was instituted in fifteen active untreated lepromatous leprosy cases for a period of 18 months. Clinical improvement was good with attainment of zero morphological index in about 66% cases. Bacteriological improvement was rather unsatisfactory as one case only reached zero level. Side effects were observed in few cases necessitating withdrawal of combined therapy and patients' prothionamide compliance was rather unimpressive.
D000328:Adult; D003622:Dapsone / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D007539:Isonicotinic Acids / Q000008:administration & dosage*; D007918:Leprosy / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008099:Liver / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011515:Prothionamide / Q000008:administration & dosage* / Q000009:adverse effects
D007539:Isonicotinic Acids; D011515:Prothionamide; D003622:Dapsone